ArticleDiabetologia2010
ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice.
Article in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- ADP-mediated Modulation of Intracellular Calcium Responses in Chromaffin Cells: The Role of Ectonucleoside Triphosphate Diphosphohydrolase 2 on Rat Adrenal Medulla Function.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2024Article
- Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.Frontiers in endocrinology · 2022Review
- Mechanism of insulin resistance in obesity: a role of ATP.Frontiers of medicine · 2021Review
- ADP Induces Blood Glucose Through Direct and Indirect Mechanisms in Promotion of Hepatic Gluconeogenesis by Elevation of NADH.Frontiers in endocrinology · 2021Article
- Update of P2Y receptor pharmacology: IUPHAR Review 27.British journal of pharmacology · 2020Review
- ATP mediates a negative autocrine signal on stimulus-secretion coupling in mouse pancreatic β-cells.Endocrine · 2019Article
- The P2X7 receptor and pannexin-1 are involved in glucose-induced autocrine regulation in β-cells.Scientific reports · 2018Article
- Important roles of P2Y receptors in the inflammation and cancer of digestive system.Oncotarget · 2016Review
- Extracellular ATP and other nucleotides-ubiquitous triggers of intercellular messenger release.Purinergic signalling · 2016Review
- Neuroprotection Mediated by P2Y13 Nucleotide Receptors in Neurons.Computational and structural biotechnology journal · 2015Review
- Can exposure to environmental chemicals increase the risk of diabetes type 1 development?BioMed research international · 2015Review
- Purinergic P2Y1 receptors take centre stage in autocrine stimulation of human beta cells.Diabetologia · 2014Article
- Impairment of vesicular ATP release affects glucose metabolism and increases insulin sensitivity.Scientific reports · 2014Article
- The enteric nervous system of P2Y13 receptor null mice is resistant against high-fat-diet- and palmitic-acid-induced neuronal loss.Purinergic signalling · 2014Article
- Role of the ubiquitin-proteasome system in the regulation of P2Y13 receptor expression: impact on hepatic HDL uptake.Cellular and molecular life sciences : CMLS · 2014Article
- Purinergic signalling in endocrine organs.Purinergic signalling · 2014Review
- Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists.PloS one · 2014Article
- Nucleolin down-regulation is involved in ADP-induced cell cycle arrest in S phase and cell apoptosis in vascular endothelial cells.PloS one · 2014Article
- High glucose and free fatty acids induce beta cell apoptosis via autocrine effects of ADP acting on the P2Y(13) receptor.Purinergic signalling · 2013Article
- The impact of commercially available purinergic ligands on purinergic signalling research.Purinergic signalling · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesesTo investigate the effects of extracellular purines on insulin secretion from mouse pancreatic islets.
methodsMouse islets and beta cells were isolated and examined with mRNA real-time quantification, cAMP quantification and insulin and glucagon secretion. ATP release was measured in MIN6c4 cells. Insulin and glucagon secretion were measured in vivo after glucose injection.
resultsEnzymatic removal of extracellular ATP at low glucose levels increased the secretion of both insulin and glucagon, while at high glucose levels insulin secretion was reduced and glucagon secretion was stimulated, indicating an autocrine effect of purines. In MIN6c4 cells it was shown that glucose does induce release of ATP into the extracellular space. Quantitative real-time PCR demonstrated the expression of the ADP receptors P2Y(1) and P2Y(13) in both intact mouse pancreatic islets and isolated beta cells. The stable ADP analogue 2-MeSADP had no effect on insulin secretion. However, co-incubation with the P2Y(1) antagonist MRS2179 inhibited insulin secretion, while co-incubation with the P2Y(13) antagonist MRS2211 stimulated insulin secretion, indicating that ADP acting via P2Y(1) stimulates insulin secretion, while signalling via P2Y(13) inhibits the secretion of insulin. P2Y(13) antagonism through MRS2211 per se increased the secretion of both insulin and glucagon at intermediate (8.3 mmol/l) and high (20 mmol/l) glucose levels, confirming an autocrine role for ADP. Administration of MRS2211 during glucose injection in vivo resulted in both increased secretion of insulin and reduced glucose levels. CONCLUSIONS/
interpretationIn conclusion, ADP acting on the P2Y(13) receptors inhibits insulin release. An antagonist to P2Y(13) increases insulin release and could be evaluated for the treatment of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.